Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fulciniti

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Leukemia|February 19, 2013
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategyT Scullen, L Santo, S Vallet, et al.
Leukemia|August 9, 2013
Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myelomaX Wang, Z Yan, M Fulciniti, et al.
Oncogene|April 23, 2013
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growthR Lu, J Pal, L Buon, et al.
Leukemia|May 2, 2008
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivoM A Shammas, H Koley, R C Bertheau, et al.
Leukemia|November 22, 2017
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myelomaA Gullà, T Hideshima, G Bianchi, et al.
Blood Cancer Journal|January 16, 2016
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growthM Fulciniti, N Amodio, R L Bandi, et al.
Cell Death & Disease|November 30, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1N Amodio, M T Di Martino, U Foresta, et al.
Leukemia|June 8, 2017
Nucleotide excision repair is a potential therapeutic target in multiple myelomaR Szalat, M K Samur, M Fulciniti, et al.
Leukemia|August 22, 2015
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myelomaR H Prabhala, M Fulciniti, D Pelluru, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Leukemia|February 19, 2013
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategyT Scullen, L Santo, S Vallet, et al.
Leukemia|August 9, 2013
Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myelomaX Wang, Z Yan, M Fulciniti, et al.
Oncogene|April 23, 2013
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growthR Lu, J Pal, L Buon, et al.
Leukemia|May 2, 2008
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivoM A Shammas, H Koley, R C Bertheau, et al.
Leukemia|November 22, 2017
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myelomaA Gullà, T Hideshima, G Bianchi, et al.
Blood Cancer Journal|January 16, 2016
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growthM Fulciniti, N Amodio, R L Bandi, et al.
Cell Death & Disease|November 30, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1N Amodio, M T Di Martino, U Foresta, et al.
Leukemia|June 8, 2017
Nucleotide excision repair is a potential therapeutic target in multiple myelomaR Szalat, M K Samur, M Fulciniti, et al.
Leukemia|August 22, 2015
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myelomaR H Prabhala, M Fulciniti, D Pelluru, et al.
Pageof 1